Cargando…

DNA Damage Response and Immune Defense

DNA damage is the cause of numerous human pathologies including cancer, premature aging, and chronic inflammatory conditions. The DNA damage response (DDR), in turn, coordinates DNA damage checkpoint activation and promotes the removal of DNA lesions. In recent years, several studies have shown how...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nastasi, Claudia, Mannarino, Laura, D’Incalci, Maurizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588887/ https://www.ncbi.nlm.nih.gov/pubmed/33053746 http://dx.doi.org/10.3390/ijms21207504

Ejemplares similares

Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer
por: Paracchini, Lara, et al.
Publicado: (2022)

Liquid Biopsy in the Clinical Management of High-Grade Serous Epithelial Ovarian Cancer—Current Use and Future Opportunities
por: Paracchini, Lara, et al.
Publicado: (2021)

DNA Damage Response and Immune Defense: Links and Mechanisms
por: Nakad, Rania, et al.
Publicado: (2016)

Editorial: Trabectedin, lurbinectedin, and other marine-derived anticancer alkaloids on solid cancer: Mechanisms of action, clinical impact, and future perspectives
por: Zambelli, Alberto, et al.
Publicado: (2023)

Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma
por: Hiltbrunner, Stefanie, et al.
Publicado: (2021)

Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment
por: Allavena, Paola, et al.
Publicado: (2022)

Trabectedin and Plitidepsin: Drugs from the Sea that Strike the Tumor Microenvironment
por: Galmarini, Carlos M., et al.
Publicado: (2014)

DNA damage and sequence specificity of DNA binding of the new anti-cancer agent 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis maleate)
por: Broggini, M., et al.
Publicado: (1990)

Inhibition of tumor‐associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti‐PD‐1 therapy
por: Belgiovine, Cristina, et al.
Publicado: (2021)

Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents
por: Colella, G, et al.
Publicado: (1999)

Is PDGFR an important target for E-3810?
por: Damia, Giovanna, et al.
Publicado: (2012)

New activities for the anti-tumor agent trabectedin: taking two birds with one stone
por: D'Incalci, Maurizio, et al.
Publicado: (2013)

3-methyladenine-DNA-glycosylase and O6-alkyl guanine-DNA-alkyltransferase activities and sensitivity to alkylating agents in human cancer cell lines.
por: Damia, G., et al.
Publicado: (1996)

Response of chemically induced primary colon tumours of the mouse to flavone acetic acid (NSC 347 512).
por: Pratesi, G., et al.
Publicado: (1988)

Trabectedin modulates the senescence-associated secretory phenotype and promotes cell death in senescent tumor cells by targeting NF-κB
por: Camorani, Simona, et al.
Publicado: (2018)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

Trabectedin: A drug from the sea that strikes tumor-associated macrophages
por: Allavena, Paola, et al.
Publicado: (2013)

Response to flavone acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenografts.
por: Giavazzi, R., et al.
Publicado: (1988)

Regional and temporal heterogeneity of epithelial ovarian cancer tumor biopsies: implications for therapeutic strategies
por: Paracchini, Lara, et al.
Publicado: (2016)

ROS Defense Systems and Terminal Oxidases in Bacteria
por: Borisov, Vitaliy B., et al.
Publicado: (2021)

Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia.
por: Colombo, T., et al.
Publicado: (1996)

Correction: Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin
por: Bello, Ezia, et al.
Publicado: (2020)

Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin
por: Bello, Ezia, et al.
Publicado: (2019)

Acute systemic DNA damage in youth does not impair immune defense with aging
por: Pugh, Jason L., et al.
Publicado: (2016)

α-Bromoacryloyl derivative of distamycin A (PNU 151807): a new non-covalent minor groove DNA binder with antineoplastic activity
por: Marchini, S, et al.
Publicado: (1999)

Tumor treating fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations
por: Mannarino, Laura, et al.
Publicado: (2022)

Important functional role of the protein osteopontin in the progression of malignant pleural mesothelioma
por: Digifico, Elisabeth, et al.
Publicado: (2023)

A systems biology approach to investigate the mechanism of action of trabectedin in a model of myelomonocytic leukemia
por: Mannarino, L, et al.
Publicado: (2018)

Flow cytometric analysis of DNA content in human ovarian cancers.
por: Erba, E., et al.
Publicado: (1989)

Stabilization of quadruplex DNA perturbs telomere replication leading to the activation of an ATR-dependent ATM signaling pathway
por: Rizzo, Angela, et al.
Publicado: (2009)

Treatment with inhibitors of polyamine biosynthesis, which selectively lower intracellular spermine, does not affect the activity of alkylating agents but antagonizes the cytotoxicity of DNA topoisomerase II inhibitors.
por: Desiderio, M. A., et al.
Publicado: (1997)

Impact of DNA Damage Response—Targeted Therapies on the Immune Response to Tumours
por: Lutfi, Nura, et al.
Publicado: (2021)

Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy
por: Huang, Jau-Ling, et al.
Publicado: (2022)

Time dependence of the in vitro cytotoxicity of hexamethylmelamine and its metabolites.
por: D'Incalci, M., et al.
Publicado: (1980)

Trabectedin, a drug acting on both cancer cells and the tumour microenvironment
por: D'Incalci, M, et al.
Publicado: (2014)

Synergism between 5-fluorouracil and N-methylformamide in HT29 human colon cancer line.
por: Laudonio, N., et al.
Publicado: (1990)

Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid.
por: Erba, E., et al.
Publicado: (1994)

Role of membrane folate-binding protein in the cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cell lines in vitro.
por: Sen, S., et al.
Publicado: (1996)

Replication Stress, DNA Damage, Inflammatory Cytokines and Innate Immune Response
por: Ragu, Sandrine, et al.
Publicado: (2020)

DNA Damage Response in the Adaptive Arm of the Immune System: Implications for Autoimmunity
por: Manolakou, Theodora, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ikvaore9cs8knl5qn2jjcr2hjk